Venture Capital Funding Quarterly
Biotechnology • Pharmaceuticals • Medical Devices
4th Quarter, 2008 – United States
Published by: VentureDeal
Life Science companies secured $2.05 billion in venture capital financing during the fourth quarter of 2008, representing a 5% decrease versus the third quarter. This continues the downward trend of funding for the three sectors of Biotechnology, Medical Devices and Pharmaceuticals. The funding was allocated between 212 companies, an 8% increase versus the previous quarter in the aggregate.
The Biotechnology sector received the most amount of funding by a slight margin, raising $767 million among 82 companies. The Pharma sector came in second with $727 million, representing a 28% increase versus the previous quarter, and reversing its downward trend. Medical Device startups received $555 million between 81 companies, a whopping 46% decrease in amounts funded.
Biotechnology funding bucked its previous downward trend by posting significantly increased funding amounts and numbers of companies funded. The largest venture financing during the quarter was Biolex' $60 million fourth round. The company said it would use the proceeds to complete phase III trials for its lead product Locteron, focused on the treatment of chronic hepatitis C.
Other notable activity in the space included the following financing events:
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
Founded in 2006, VentureDeal is a database that provides the latest information about venture capital firms, venture-backed technology companies and transactions throughout North America.
Learn More »
© 2016 VentureDeal, Inc., Menlo Park, CA. All Rights Reserved.